All In Biotech

Drug Trial Radar · NCT05933057

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Feb 19, 2024

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
ItalfarmacoIndustry
Sponsor type
Industry
Collaborators
Fortrea
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 9 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months. * Planned screening duration: approximately 4 weeks (±14 days) * Planned treatment duration: 18 months (approximately 72 weeks) * Planned follow-up duration: 4 weeks (±7 days) (for patients not participating in the long-term safety study) * Total duration of study participation: up to 83 weeks (ie, 20-21 months)

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • GivinostatDrug

    Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.

  • PlaceboDrug

    Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Performance of Upper Limb 2.0 (PUL) total score at 18 months of treatment of givinostat compared to placebo group.Time frame: Baseline and 18 months

Locations

29 sites in 12 countries. Site status is shown where the registry gives one.

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium · Recruiting

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • The University of Western Ontario - Children's Health Research Institute

    London, Ontario, Canada · Recruiting

  • University of Ottawa - Children's Hospital of Eastern Ontario

    Ottawa, Ontario, Canada · Recruiting

  • University of Toronto - Holland Bloorview Kids Rehabilitation Hospital

    Toronto, Ontario, Canada · Recruiting

  • Klinika dětské neurologie 2. LF, Fakultní nemocnice v Motole

    Prague, Czechia · Not yet recruiting

  • Centre Hospitalier Régional Universitaire de Lille

    Lille, France · Recruiting

  • Centre hospitalier universitaire - Hôpitaux de Marseille

    Marseille, France · Recruiting

  • Hôpital Armand-Trousseau - I-Motion

    Paris, France · Recruiting

  • Charite-Universitaetsmedizin Berlin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Essen Kinder-und Jugendmedizin Neuropadiatrie

    Essen, Germany · Not yet recruiting

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Kinder- und Jugendmedizin

    Hamburg, Germany · Not yet recruiting

  • Associazione La Nostra Famiglia - IRCCS Eugenio Medea - Bosisio Parini

    Lecco, Italy · Recruiting

  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscular Omnicentre

    Milan, Italy · Recruiting

  • Università degli Studi di Padova - Azienda Ospedaliera di Padova

    Padova, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy · Recruiting

  • Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore

    Roma, Italy · Recruiting

  • Leids Universitair Medisch Centrum (LUMC)

    Leiden, Netherlands · Recruiting

  • Radboud Universitair Medisch Centrum (Radboudumc)

    Nijmegen, Netherlands · Recruiting

  • Uniwersyteckie Centrum Kliniczne, Klinika Neurologii Rozwojowej

    Gdansk, Poland · Not yet recruiting

  • Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny

    Warsaw, Poland · Not yet recruiting

  • Clinic of Neurology and Psychiatry for Children and Youth

    Belgrade, Serbia · Not yet recruiting

  • Hospital Sant Joan de Déu

    Barcelona, Spain · Recruiting

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain · Recruiting

  • Karolinska University Hospital, Solna CKB Centrum för Kliniska Barnstudier

    Stockholm, Sweden · Not yet recruiting

  • Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University

    Newcastle upon Tyne, England, United Kingdom · Active not recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, England, United Kingdom · Withdrawn

  • NHS Greater Glasgow and Clyde - Royal Hospital for Children

    Glasgow, Scotland, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.